Objective: To evaluate of life expectancy of patients with newly diagnosed multiple myeloma (MM) treated by high dose melphalan and frozen autologous peripheral blood stem cell transplantation at Hematology and Blood transfusion hospital.

Methods: From January 2012 to September 2015, 30 eligible patients with adequate cardiac, pulmonary and renal function who had undergone induction with bortezomib and dexamethasone (BD). Melphalan at 200 mg/m2 was used as a conditioning regimen. The median of the transfused the CD34+ cells was 5×10^6/kg.

Results: Median age was 49.1 .1±6.21 years. After a median follow-up of 26 months, the median overall and event-free survivals were 39.9±2.5 months (CI 95%, 35.1-44.9) and 28.9±3.1 months (CI 95%. 22.8-35.2), respectively. The overall survival and progressive free survival of 2 years were 83% và 59.5%, resprectively.

Conclusions: Autologous stem cell transplantation (ASCT) helps to prolong MM patient survival.